Sign inCreate Account
At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category of drugs - SGLT-2 inhibitors or gliflozins.
NEWS
BUSINESS
MOVIES
CRICKET
SPORTS
GET AHEAD
REDIFF MONEY
REDIFF-TV
REDIFF ASTRO